Cumberland Pharmaceuticals Inc.
CPIX
$4.35
-$1.01-18.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.75M | 36.54M | 34.75M | 35.75M | 36.79M |
| Total Other Revenue | 1.33M | 1.33M | 2.04M | 2.04M | 2.04M |
| Total Revenue | 41.08M | 37.87M | 36.79M | 37.79M | 38.83M |
| Cost of Revenue | 6.44M | 6.59M | 6.14M | 6.58M | 6.39M |
| Gross Profit | 34.65M | 31.28M | 30.65M | 31.20M | 32.43M |
| SG&A Expenses | 28.32M | 28.15M | 28.80M | 28.81M | 28.85M |
| Depreciation & Amortization | 4.64M | 4.75M | 4.48M | 4.58M | 4.64M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.35M | 44.30M | 44.21M | 45.38M | 45.37M |
| Operating Income | -3.27M | -6.43M | -7.43M | -7.60M | -6.55M |
| Income Before Tax | -3.32M | -6.47M | -10.78M | -10.32M | -8.36M |
| Income Tax Expenses | -28.50K | -22.80K | 59.20K | 54.70K | 50.20K |
| Earnings from Continuing Operations | -3.29 | -6.44 | -10.84 | -10.37 | -8.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.60K | -36.10K | -26.30K | -5.30K | -12.30K |
| Net Income | -3.28M | -6.48M | -10.87M | -10.38M | -8.42M |
| EBIT | -3.27M | -6.43M | -7.43M | -7.60M | -6.55M |
| EBITDA | 1.51M | -1.53M | -2.79M | -2.83M | -1.72M |
| EPS Basic | -0.24 | -0.46 | -0.77 | -0.73 | -0.60 |
| Normalized Basic EPS | -0.16 | -0.30 | -0.34 | -0.32 | -0.24 |
| EPS Diluted | -0.25 | -0.47 | -0.78 | -0.74 | -0.60 |
| Normalized Diluted EPS | -0.16 | -0.30 | -0.34 | -0.32 | -0.24 |
| Average Basic Shares Outstanding | 57.08M | 56.24M | 56.43M | 56.66M | 56.93M |
| Average Diluted Shares Outstanding | 57.40M | 56.24M | 56.43M | 56.66M | 57.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |